جميع الدراسات
مُصرحالتأكيد العلاجي (المرحلة الثالثة)تداخلي

A Phase 1/2/3, Open-Label, Dose Escalation, Dose Expansion, and Randomized, Controlled Study to Evaluate the Safety and Efficacy of ATSN-201 Gene Therapy in Subjects with RS1-Associated X-linked Retinoschisis (LIGHTHOUSE)

X-linked retinoschisis (XLRS) is an inherited eye condition that affects the retina, the light-sensitive lining at the back of the eye. A change in a gene called RS1 causes the layers of the retina to split, which leads to blurred vision and sight problems from an early age. The LIGHTHOUSE trial is looking at a new gene therapy called ATSN-201. The treatment works by delivering a healthy, working copy of the RS1 gene directly into the eye. Doctors want to learn whether this treatment is safe and if it can repair retinal structure, improve reading speed, and help people see better in both normal and dim light. Participants will have thorough eye examinations, specialised retinal scans, and regular check-ups with eye specialists. This research aims to find out if gene therapy could become a helpful treatment for this lifelong condition.

نظرة سريعة

الحالة
مُصرح
المرحلة
التأكيد العلاجي (المرحلة الثالثة)
الراعي
Atsena Therapeutics Inc.
الهدف من التسجيل
36
ابدأ
28 Sep 2026

ما هو موضوع هذه الدراسة؟

The retina acts like the film in a camera, capturing light and sending pictures to your brain. In people with X-linked retinoschisis (XLRS), a problem in a gene known as RS1 stops the eye from making an important protein called retinoschisin. Without this protein, the delicate layers of the retina can split and form small fluid-filled spaces. Over time, this causes central vision to become blurry and makes reading or seeing in low light difficult.

The LIGHTHOUSE clinical trial is investigating whether a gene therapy called ATSN-201 can help. Gene therapy is designed to tackle the root cause of a genetic illness rather than just managing the symptoms. ATSN-201 uses a harmless, modified carrier to deliver a normal copy of the RS1 gene straight to the retinal cells, aiming to help the eye produce the missing protein and hold the retinal layers together.

Doctors will carefully assess how well the treatment works and check for any unwanted side effects. They will test how sensitive the retina is to tiny points of light, measure reading ability, and take detailed 3D scans of the back of the eye. If successful, this trial could represent an important step forward in finding a lasting treatment to protect and potentially improve vision for people with XLRS.

النقاط الرئيسية

  • The LIGHTHOUSE trial tests ATSN-201 gene therapy for RS1-associated X-linked retinoschisis.
  • The treatment aims to deliver a working RS1 gene to repair retinal layers and protect vision.
  • Participation involves eye scans, reading tests, an eye procedure, and regular check-ups.
  • The study evaluates safety, light sensitivity, and improvements in daily sight.
  • Taking part is entirely voluntary and you can withdraw at any time.

من قد يكون مؤهلاً؟

This trial is designed for people who have been diagnosed with X-linked retinoschisis linked to changes in the RS1 gene. A genetic test confirming a mutation in the RS1 gene is usually required.

According to the main trial criteria, participants are generally adults aged 18 and older, although certain parts of the research may evaluate younger age groups. Participants must also have measurable vision changes that allow doctors to track any improvements during the study.

You may not be eligible if you have other serious eye diseases, have had certain types of eye surgery recently, or have health conditions that make taking part unsafe. The study team will review your full medical history and perform detailed eye tests to confirm if the study is suitable for you.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. You have a confirmed diagnosis of X-linked retinoschisis (XLRS).
  2. You have genetic confirmation of an RS1 gene fault.
  3. You are aged 18 or older (or meet specific age criteria for certain study groups).
  4. You have noticeable vision loss but still have some usable central sight.
  5. You are able to attend regular eye clinic appointments and undergo eye scans.
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

Taking part in this study begins with screening visits where doctors carry out detailed eye tests, vision chart checks, and harmless light scans of your retina. If you are eligible, you will receive the ATSN-201 treatment in one eye, typically given as a specialised procedure in an operating room by an experienced eye surgeon.

After receiving the treatment, you will need to attend regular follow-up visits. During these appointments, the medical team will examine your eyes, test your reading speed, check your vision in dim light, and monitor how your retina is healing. You will also be asked questions about how your sight affects your everyday life.

The study involves close monitoring over several months to a few years to ensure your safety and to see how long any potential benefits last. Travel expenses for study visits are usually reimbursed.

المخاطر والفوائد المحتملة

The potential benefit of joining this study is that the gene therapy may help repair retinal layers and improve or stabilise your vision, although this cannot be guaranteed. Potential risks include side effects from the procedure, such as temporary eye discomfort, inflammation, bleeding, infection, or changes in eye pressure. The study medicine could also cause unforeseen side effects. Taking part is completely voluntary. You are free to withdraw at any time without giving a reason, and your regular NHS medical care will not be affected in any way.

المواقع (6)

بعض مواقع الأماكن تقريبية. نحن نعمل على تحسين ذلك — يرجى التحقق مع فريق التجربة قبل السفر.
  • —
    غير مؤكد
    إيطاليا
  • —
    غير مؤكد
    ألمانيا
  • —
    غير مؤكد
    إسبانيا
  • —
    غير مؤكد
    هولندا
  • —
    غير مؤكد
    فرنسا
  • —
    غير مؤكد
    بلجيكا

أسئلة شائعة

What is X-linked retinoschisis?

It is an inherited condition that mainly affects males, causing the layers of the retina at the back of the eye to split and blur central vision.

How does ATSN-201 gene therapy work?

It delivers a healthy copy of the RS1 gene directly into the retina to help the eye make the protein needed to keep retinal layers together.

Will both of my eyes be treated?

In clinical trials like this, gene therapy is usually given to only one eye so doctors can carefully monitor safety and compare results.

Do I have to pay to take part in the trial?

No, you do not pay for the study treatment or tests. Most clinical studies also help cover reasonable travel and parking costs.

هل يمكنني مغادرة الدراسة إذا غيرت رأيي؟

Yes, you can leave the study at any point. Your decision will not affect the quality of your usual eye care or relationship with your doctors.

كيفية معرفة المزيد

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.